Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Dr. Gavin Corcoran to its Board of Directors. Dr. Corcoran, currently Chief Development Officer at Formation Bio, brings extensive pharmaceutical experience from leadership positions at Sio Gene Therapies, Allergan, and Stiefel Laboratories.
The appointment comes at a important time as Verrica experiences growing commercial success with YCANTH®, its treatment for molluscum contagiosum, which is gaining increased adoption among dermatologists and pediatricians. The company aims to leverage Dr. Corcoran's expertise in developing innovative medicines and executing strategic transactions to advance its late-stage dermatology pipeline.
Verrica Pharmaceuticals (Nasdaq: VRCA) ha nominato il Dr. Gavin Corcoran nel suo Consiglio di Amministrazione. Il Dr. Corcoran, attualmente Chief Development Officer di Formation Bio, porta con sé una vasta esperienza nel settore farmaceutico, avendo ricoperto ruoli di leadership presso Sio Gene Therapies, Allergan e Stiefel Laboratories.
Questa nomina arriva in un momento importante, poiché Verrica sta vivendo un crescente successo commerciale con YCANTH®, il suo trattamento per il mollusco contagioso, che sta ottenendo sempre maggiore adozione tra dermatologi e pediatri. L'azienda mira a sfruttare l'expertise del Dr. Corcoran nello sviluppo di medicinali innovativi e nell'esecuzione di transazioni strategiche per far avanzare il suo pipeline dermatologico in fase avanzata.
Verrica Pharmaceuticals (Nasdaq: VRCA) ha nombrado al Dr. Gavin Corcoran en su Junta Directiva. El Dr. Corcoran, actualmente Director de Desarrollo en Formation Bio, aporta una amplia experiencia farmacéutica de puestos de liderazgo en Sio Gene Therapies, Allergan y Stiefel Laboratories.
La designación llega en un momento importante, ya que Verrica experimenta un creciente éxito comercial con YCANTH®, su tratamiento para el molusco contagioso, que está ganando una mayor adopción entre dermatólogos y pediatras. La empresa busca aprovechar la experiencia del Dr. Corcoran en el desarrollo de medicamentos innovadores y en la ejecución de transacciones estratégicas para avanzar en su cartera de dermatología en etapa avanzada.
Verrica Pharmaceuticals (Nasdaq: VRCA)는 이사회의 일원으로 Dr. Gavin Corcoran을 임명했습니다. Corcoran 박사는 현재 Formation Bio의 개발 책임자로 재직 중이며, Sio Gene Therapies, Allergan 및 Stiefel Laboratories에서의 리더십 경험을 바탕으로 광범위한 제약 경험을 제공합니다.
이번 임명은 Verrica가 피부과 의사와 소아과 의사들 사이에서 점점 더 많은 채택을 받고 있는 YCANTH®로 상업적 성공을 거두고 있는 중요한 시점에 이루어졌습니다. 회사는 Corcoran 박사의 혁신적인 의약품 개발 및 전략적 거래 실행에 대한 전문성을 활용하여 후기 단계의 피부과 파이프라인을 발전시키는 것을 목표로 하고 있습니다.
Verrica Pharmaceuticals (Nasdaq: VRCA) a nommé le Dr. Gavin Corcoran au sein de son Conseil d'Administration. Le Dr. Corcoran, actuellement Directeur du Développement chez Formation Bio, apporte une vaste expérience pharmaceutique acquise à des postes de direction chez Sio Gene Therapies, Allergan et Stiefel Laboratories.
Cette nomination intervient à un moment crucial, alors que Verrica connaît un succès commercial croissant avec YCANTH®, son traitement contre le molluscum contagiosum, qui est de plus en plus adopté par les dermatologues et pédiatres. L'entreprise vise à tirer parti de l'expertise du Dr. Corcoran dans le développement de médicaments innovants et l'exécution de transactions stratégiques pour faire avancer son pipeline dermatologique en phase avancée.
Verrica Pharmaceuticals (Nasdaq: VRCA) hat Dr. Gavin Corcoran in seinen Vorstand berufen. Dr. Corcoran, der derzeit Chief Development Officer bei Formation Bio ist, bringt umfangreiche Erfahrung in der Pharmaindustrie aus Führungspositionen bei Sio Gene Therapies, Allergan und Stiefel Laboratories mit.
Die Ernennung erfolgt zu einem wichtigen Zeitpunkt, da Verrica mit YCANTH®, seiner Behandlung gegen Molluscum contagiosum, die zunehmend von Dermatologen und Kinderärzten angenommen wird, wachsenden kommerziellen Erfolg verzeichnet. Das Unternehmen strebt an, Dr. Corcorans Expertise in der Entwicklung innovativer Medikamente und der Durchführung strategischer Transaktionen zu nutzen, um seine fortgeschrittene Dermatologie-Pipeline voranzutreiben.
- Growing commercial adoption of YCANTH® among healthcare providers
- Strategic board appointment bringing expertise in drug development and transactions
- Advancing late-stage pipeline targeting unmet dermatology needs
- None.
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors.
“We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly accomplished pharmaceutical executive with an outstanding track record of successfully developing and launching innovative medicines, as well as creating significant value through strategic transactions. As Verrica continues to grow its commercial business and advance its late-stage pipeline, Gavin’s insights and experience will be extremely helpful as we seek to achieve our strategic objectives.”
“Verrica is now reaching an important inflection point in its commercial business, as a growing number of dermatologists and pediatricians are prescribing YCANTH® for the treatment of molluscum contagiosum,” said Dr. Corcoran. “As the company’s commercial business continues to grow, I also see tremendous potential in Verrica’s innovative clinical development pipeline, which, like YCANTH®, seeks to address large areas of unmet medical need in dermatology. I look forward to working with my fellow Board Members and Verrica’s management team to help bring these therapies to patients.”
Dr. Corcoran has served as the Chief Development Officer of Formation Bio since November 2021. He previously held several R&D leadership positions including Chief Research and Development Officer at Sio Gene Therapies, Inc. (formerly known as Axovant), Chief Medical Officer at Allergan and Head of R&D at Stiefel Laboratories. He received his M.B. B.Ch. from the University of Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.
About YCANTH® (VP-102)
YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH® is the first and only commercially available product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH® was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH® was a safe and effective therapeutic for the treatment of molluscum. Approximately 225 million lives are eligible to receive YCANTH® covered by insurance. YCANTH® is available to all patients with and without insurance coverage for
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH and the clinical development and benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2024 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
What is the significance of Dr. Gavin Corcoran joining VRCA's Board of Directors?
How is VRCA's YCANTH® performing in the market?
What is Dr. Corcoran's current role and previous experience?
What are VRCA's current strategic objectives?
